# Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)

> **NCT00744081** · PHASE2 · COMPLETED · sponsor: **Goethe University** · enrollment: 130 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Glivec
- **DRUG:** Mitoxantrone
- **DRUG:** Topotecan
- **DRUG:** AraC

## Key facts

- **NCT ID:** NCT00744081
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744081, "Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00744081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*